Financial Support

OPKO Connect provides comprehensive support

OPKO Connect offers support for your office on behalf of your patients who have been prescribed Rayaldee^® (calcifediol).

Benefits Investigation

OPKO Connect will verify the patient’s insurance coverage for Rayaldee, including identifying

•	Prior authorization requirements
•	Deductible, co-insurance, and out-of-pocket costs

Prior Authorization (PA) Assistance

OPKO Connect services are described in a circle: Benefits investigation, prior authorization support, appeals support, copay assistance programs, patient assistance programs, general support/assistance.

OPKO Connect will assist with any insurance-required PAs for Rayaldee by

•	Completing and submitting insurer-specific PA forms
•	Confirming receipt of submission by insurance and facilitating a timely review
•	Providing status from insurance to patients and their healthcare provider’s office

Support for Appeals if the PA is Denied

OPKO Connect will

•	Confirm the reason for the PA denial and provide options for appeals submission
•	Supply a letter of medical necessity (LMN) template specific to Rayaldee
•	Provide appeal status from insurance to patients and their healthcare provider’s office

Copay Assistance

Eligible, commercially insured patients can fill their Rayaldee prescription for $5 per month until the annual maximum limit is reached.

*	Eligible, commercially insured patients can fill their Rayaldee prescription for $5 per month.

Patient Assistance Program (PAP)

For patients without Rayaldee pharmacy insurance coverage, OPKO Connect has a patient assistance program offering free medication. Eligibility criteria apply and annual reenrollment is required.

Download the application for patient assistance.

•	English
•	Spanish
•	Mandarin

*	Eligible, commercially insured patients can fill their Rayaldee prescription for $5 per month.

To receive support for your patients, please complete a Rayaldee Service Request Form (SRF) and return to OPKO Connect.

•	Fax 1-844-660-7083
•	Email opkoconnect@rxallcare.com

OPKO Connect services are available

by phone at 1-844-414-6756
or by email opkoconnect@rxallcare.com
Monday through Friday, 8am to 8pm ET

Download the Rayaldee Service Request Form.

Download a letter of medical necessity.

Download an attestation letter for patients with vitamin D insufficiency.

Important Safety Information

•	Hypercalcemia: Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium.
•	Digitalis toxicity: Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee.
•	Adynamic Bone Disease: Monitor for abnormally low levels of intact parathyroid hormone (iPTH) levels when using Rayaldee, and adjust dose if needed.
•	The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
•	Care should be taken while dosing Rayaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions.
•	Serum calcium should be below 9.8 mg/dL before initiating treatment.
•	Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and iPTH 3 months after starting therapy or changing dose.

Please see Full Prescribing Information.

Indication and Limitations of Use

Rayaldee^® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

Important Safety Information

•	Hypercalcemia: Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium.
•	Digitalis toxicity: Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee.
•	Adynamic Bone Disease: Monitor for abnormally low levels of intact parathyroid hormone (iPTH) levels when using Rayaldee, and adjust dose if needed.
•	The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
•	Care should be taken while dosing Rayaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions.
•	Serum calcium should be below 9.8 mg/dL before initiating treatment.
•	Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and iPTH 3 months after starting therapy or changing dose.

Please see Full Prescribing Information.